The Cost-Effectiveness of Canagliflozin Versus Sitagliptin as Third-Line Therapy in Type 2 Diabetes Mellitus (T2dm) in a Canadian setting
May 1, 2015, 00:00
10.1016/j.jval.2015.03.355
https://www.valueinhealthjournal.com/article/S1098-3015(15)00412-X/fulltext
Title :
The Cost-Effectiveness of Canagliflozin Versus Sitagliptin as Third-Line Therapy in Type 2 Diabetes Mellitus (T2dm) in a Canadian setting
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(15)00412-X&doi=10.1016/j.jval.2015.03.355
First page :
A61
Section Title :
Diabetes/Endocrine Disorders
Open access? :
No
Section Order :
1458